Press release: Ncardia Launches First-of-Its-Kind iPSC-Derived Non-Human Primate Cardiomyocytes to Advance Cardiac Safety Research

Published on October 9, 2025
Press release: Ncardia Launches First-of-Its-Kind iPSC-Derived Non-Human Primate Cardiomyocytes to Advance Cardiac Safety Research

Leiden, September 22, 2025 – Ncardia, a leader in stem cell–based solutions for drug discovery and safety assessment, today announced the launch of Ncyte® NHP-C vCardiomyocytes, the first commercially available ventricular-like cardiomyocytes derived from induced pluripotent stem cells (iPSCs) of cynomolgus monkeys. New Ncyte® NHP-C vCardiomyocytes provide a scalable, ethical, and translational tool for cross-species cardiac studies

Continue reading on website
Other news

Commentary: Bonds of friendship can create lifesaving teams

October 8, 2025
Commentary: Bonds of friendship can create lifesaving teams Jodi_Lewis Wed, 10/08/2025 - 12:16Read more about Commentary: Bonds of friendship can create lifesaving teamsThis commentary piece appeared in the print version of t

Outsourced Pharma: Navigating The Pathway Towards Regulatory Approval: The Chemistry & Challenges Behind Antibody-Oligonucleotide Conjugates (AOCs)

October 13, 2025
Antibody-oligonucleotide conjugates (AOCs) are an emerging and exciting development in precision medicine. AOCs combine the specificity of antibodies with the gene-modulating potential of oligonucleotides (Oligos), allowing them to act directly on gene expression within targeted cells while simultaneously addressing longstanding challenges in oligo drug delivery. This dual capability opens doors t